CHICAGO — In this Healio Video Perspective, Arshad M. Khanani, MD, MA, FASRS, discusses the efficacy of Zimura for the treatment of geographic atrophy in the GATHER2 phase 3 study presented at Retina Subspecialty Day at the AAO meeting.
“The GATHER2 pivotal study met the primary prespecified endpoint, and we saw an early therapeutic effect that increased over time, very consistent with the GATHER1 study results,” Khanani said. “Avacincaptad pegol is the first investigational therapy in geographic atrophy to achieve the 12-month prespecified primary endpoint in two phase